Fragmin 5000 j.m. a.Xa/0,2 ml

Aperçu du produit

About Fragmin 5000 j.m. a.Xa/0,2 ml

Fragmin 5000 j.m. a.Xa/0,2 ml is a prescription anticoagulant medication used to prevent and treat blood clots. It is supplied in a prefilled syringe containing 0.2 milliliters of solution, which delivers a precise dose of 5,000 units of the active ingredient. The product is manufactured under strict quality controls to ensure safety and efficacy for patients requiring anticoagulation therapy. Fragmin is commonly prescribed for the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing orthopedic surgery or other high‑risk procedures. It may also be used to treat acute venous thromboembolism and to reduce the risk of recurrent clots in certain clinical settings. The medication is administered via subcutaneous injection, typically once daily, and is designed to provide consistent anticoagulant effects throughout the treatment period.

Key Benefits & Uses

• Effective prevention of deep vein thrombosis and pulmonary embolism.
• Targeted treatment for acute venous thromboembolism.
• Convenient prefilled syringe for accurate dosing.

Active Ingredient & Action

The active ingredient in Fragmin 5000 j.m. a.Xa/0,2 ml is a low‑molecular‑weight heparin that selectively inhibits factor Xa, a key enzyme in the coagulation cascade. By blocking factor Xa, the drug reduces the conversion of prothrombin to thrombin, thereby decreasing clot formation and promoting the dissolution of existing clots. This mechanism provides a predictable anticoagulant effect with a lower risk of bleeding complications compared to some older anticoagulants.

Important Notes

Fragmin should only be used under the supervision of a qualified healthcare professional. Patients should inform their doctor of any history of bleeding disorders, kidney disease, or concurrent use of other anticoagulants. The medication is not suitable for individuals with severe renal impairment without dosage adjustment. Proper storage at room temperature and adherence to the prescribed injection schedule are essential for optimal safety and effectiveness. If any signs of unusual bleeding or bruising occur, patients should seek medical attention promptly.